Chemotherapy News and Research

Latest Chemotherapy News and Research

Prostate cancer drug, Omnitarg by Genentech falls short

Research into an experimental prostate cancer drug being developed by Genentech Inc. will probably be abandoned after scientists found that the drug failed to prove effective in a mid-stage trial.

15 May 2005

Great news for breast cancer patients

In encouraging new study results researchers say that modern treatments have significantly boosted the 15-year survival rate for breast cancer, and even better news is that they have also found that drug and hormonal therapies effectively cure many women, rather than simply delaying the recurrence of disease.

12 May 2005

Discovery may pave way for immunotherapies for prostate cancer

Using a common chemotherapy agent, researchers at UCLA's Jonsson Cancer Center and the Department of Pathology and Laboratory Medicine found a way to move an important biomarker expressed in prostate cancer, shaking it loose from one location in a cell – where it could not be accessed by blood – to another, easier to target area.

11 May 2005

Laboratory model of immune system overcomes ethical constraints on studies of hematopoietic stem cells in humans

Scientists at St. Jude Children’s Research Hospital have joined with colleagues at several other institutions to develop a laboratory model of the human immune system. This model will allow scientists to study ways for improving the results of hematopoietic stem cell (HSC) transplantation without putting patients at risk.

10 May 2005

A combination of chemotherapy drugs could double survival rates for pancreatic cancer

Pancreatic cancer has a poor prognosis. More than 80% of patients present with advanced disease at diagnosis, and mortality is high. A single chemotherapy drug, gemcitabine, is regarded as the standard treatment, but it has lead to a 1-year overall survival of only 17—28% in clinical trials.

9 May 2005

Many lives may be saved by new blood test for ovarian cancer

A new blood test which has the potential to save many lives has been developed to detect ovarian cancer, a disease known as the silent killer because it is so difficult to identify.

9 May 2005

Study identifies possible marker for efficacy of gefitinib in lung cancer patients

Patients with advanced non–small-cell lung cancer (NSCLC) whose tumor cells contain extra copies of the epidermal growth factor receptor (EGFR) gene may be more likely to respond to the drug gefitinib (Iressa), and this high gene copy number may be an effective predictor of gefitinib efficacy, according to a new study in the May 4 issue of the Journal of the National Cancer Institute.

3 May 2005

Giving children access to drug clinical trials is crucial, clofarabine approval shows

The accelerated approval of the drug clofarabine to treat relapsed or refractory pediatric acute lymphoblastic leukemia (ALL) demonstrates the importance of offering children rapid access to new treatments through clinical trials, according to investigators at St. Jude Children's Research Hospital. Refractory or relapsed ALL is a disease that resists treatment.

2 May 2005

FDA to change regulations regarding side-effect information in drug ads

The Food and Drug Administration is about to make it easier for you to understand both the benefits and risks of a prescription medication, it was revealed at the Second Annual Medical Liaison Seminar sponsored here by Scientific Advantage LLC.

2 May 2005

New prognostic markers help identify risk of relapse

A recently completed clinical study has found new prognostic markers that may help clinicians identify those children with leukaemia who are at high risk of relapse and are most in need of intensified treatment to improve their chance of survival.

1 May 2005

Researchers determine mechanism of action of chemotherapy drug motexafin gadolinium

The chemotherapy drug motexafin gadolinium (brand name: Xcytrin, manufactured by Pharmacyclics, Inc.) works to thwart cancer cells by disrupting key enzymes involved in cellular metabolism, according to a team of researchers led by Joseph Hacia, Ph.D., assistant professor of biochemistry and molecular biology at the Keck School of Medicine of the University of Southern California.

1 May 2005

Cancer treatment - timing is everything

Research led by a cancer biologist at The Cleveland Clinic Lerner Research Institute has identified a molecular mechanism that links the body's internal clock to daily variations in how a patient responds to cancer treatment.

28 Apr 2005

Children treated for soft tissue sarcomas at greater risk of second cancers

A new study has found that although children treated for soft tissue sarcomas are surviving longer than they did in the past, they have an increased risk for second cancers, especially when initial treatment combined radiation and chemotherapy. This is according to analysis of data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.

27 Apr 2005

New breast cancer drug combo could save thousands of lives

New hope has been given to thousands of women living in dread of the return of an aggressive form of breast cancer.

26 Apr 2005

Herceptin in combination with chemotherapy reduces risk of breast cancer recurrence in women with with early-stage breast cancer

Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.

26 Apr 2005

Pulsating ultrasound enhances gene therapy for tumors

High-intensity focused ultrasound emitted in short pulses is a promising, non-invasive procedure for enhancing gene delivery to cancerous cells without destroying healthy tissue, according to a study in the May issue of the journal Radiology.

26 Apr 2005

Herceptin provides hope to new breast cancer sufferers

According to new research, Herceptin, Genentech's breast cancer treatment has shown promise in treating the early stages of breast cancer.

25 Apr 2005

Elderly lung cancer patients tolerate combined chemotherapy and radiotherapy with no higher risk of death than younger patients

Lung cancer remains the leading cause of cancer deaths in the U.S., with half of those diagnosed at age 70 years or older. About 20 percent of patients with lung cancer will have small cell lung cancer (SCLC). In the past, SCLC progressed rapidly despite initial chemotherapy sensitivity and few patients survive three years.

25 Apr 2005

High risk of second cancers in survivors of childhood soft tissue sarcomas

Children treated for soft tissue sarcomas have a significantly higher risk of developing subsequent cancers later in life, according to a new study. The study appears in the June 1, 2005 issue of CANCER, a peer-reviewed journal of the American Cancer Society, and indicates children treated with combined chemotherapy and radiation therapy, in particular, had greater risks of developing a new malignancy.

25 Apr 2005

Pattern of gene expression predicts multiple drug resistance, treatment failure in pediatric leukemia

The discovery of a specific pattern of gene expression linked to multiple-drug resistance of leukemic cells is giving researchers crucial information into why standard therapies fail to cure some children with acute lymphoblastic leukemia (ALL). This finding, from investigators at St. Jude Children’s Research Hospital, could lead to development of drugs that would overcome that resistance.

24 Apr 2005

Chemotherapy News and Research

Latest Chemotherapy News and Research

Prostate cancer drug, Omnitarg by Genentech falls short

Great news for breast cancer patients

Discovery may pave way for immunotherapies for prostate cancer

Laboratory model of immune system overcomes ethical constraints on studies of hematopoietic stem cells in humans

A combination of chemotherapy drugs could double survival rates for pancreatic cancer

Many lives may be saved by new blood test for ovarian cancer

Study identifies possible marker for efficacy of gefitinib in lung cancer patients

Giving children access to drug clinical trials is crucial, clofarabine approval shows

FDA to change regulations regarding side-effect information in drug ads

New prognostic markers help identify risk of relapse

Researchers determine mechanism of action of chemotherapy drug motexafin gadolinium

Cancer treatment - timing is everything

Children treated for soft tissue sarcomas at greater risk of second cancers

New breast cancer drug combo could save thousands of lives

Herceptin in combination with chemotherapy reduces risk of breast cancer recurrence in women with with early-stage breast cancer

Pulsating ultrasound enhances gene therapy for tumors

Herceptin provides hope to new breast cancer sufferers

Elderly lung cancer patients tolerate combined chemotherapy and radiotherapy with no higher risk of death than younger patients

High risk of second cancers in survivors of childhood soft tissue sarcomas

Pattern of gene expression predicts multiple drug resistance, treatment failure in pediatric leukemia

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in